Thursday, December 6, 2012
Researchers at Northwestern University and the Myelin Repair Foundation have
simplified an autologous cell-based strategy for promoting antigen-specific
tolerance by replacing splenic leukocytes with synthetic microparticles as the
antigen carrier.1 The groups are planning to first develop the
therapy and establish clinical proof of concept in autoimmune indications for
which the key antigen is known before moving forward in multiple sclerosis.
MRF and Northwestern now want to establish clinical proof of
concept for the microparticle therapy in another autoimmune-related indication
before attempting to develop it in MS.
Lou, K.-J. SciBX 5(47); doi:10.1038/scibx.2012.1226 Published online
Dec. 6, 2012
1. Getts, D.R. et al.
Nat. Biotechnol.; published online Nov. 18, 2012; doi:10.1038/nbt.2434 Contact:
Stephen D. Miller, Northwestern University, Evanston, Illinois e-mail: firstname.lastname@example.org
2. Vanderlugt, C.L. et
al. J. Immunol. 164, 670-678 (2000)
3. Turley, D.M. &
Miller, S.D. J. Immunol. 178, 2212-2220 (2007)
4. Getts, D.R. et al.
J. Immunol. 187, 2405-2417 (2011)
AND INSTITUTIONS MENTIONED
Brigham and Women's Hospital, Boston, Mass.
Myelin Repair Foundation, Saratoga, Calif.
Northwestern University, Chicago, Ill.
Stanford University School of Medicine, Stanford, Calif.